A biallelic SNIP1 Amish founder variant causes a recognizable neurodevelopmental disorder.
Zineb AmmousLettie E RawlinsHannah JonesJoseph S LeslieOlivia WengerEthan M ScottJim DelineTom HerrRebecca EvansAngela ScheidJoanna KennedyBarry A ChiozaRyan M AmesHarold E CrossErik G PuffenbergerLorna W HarriesAndrew H CrosbyAndrew H CrosbyPublished in: PLoS genetics (2021)
SNIP1 (Smad nuclear interacting protein 1) is a widely expressed transcriptional suppressor of the TGF-β signal-transduction pathway which plays a key role in human spliceosome function. Here, we describe extensive genetic studies and clinical findings of a complex inherited neurodevelopmental disorder in 35 individuals associated with a SNIP1 NM_024700.4:c.1097A>G, p.(Glu366Gly) variant, present at high frequency in the Amish community. The cardinal clinical features of the condition include hypotonia, global developmental delay, intellectual disability, seizures, and a characteristic craniofacial appearance. Our gene transcript studies in affected individuals define altered gene expression profiles of a number of molecules with well-defined neurodevelopmental and neuropathological roles, potentially explaining clinical outcomes. Together these data confirm this SNIP1 gene variant as a cause of an autosomal recessive complex neurodevelopmental disorder and provide important insight into the molecular roles of SNIP1, which likely explain the cardinal clinical outcomes in affected individuals, defining potential therapeutic avenues for future research.
Keyphrases
- intellectual disability
- high frequency
- genome wide
- copy number
- autism spectrum disorder
- transcranial magnetic stimulation
- transforming growth factor
- genome wide identification
- endothelial cells
- healthcare
- gene expression
- transcription factor
- case control
- epithelial mesenchymal transition
- photodynamic therapy
- electronic health record
- oxidative stress
- genome wide analysis
- single molecule
- deep learning
- rna seq
- single cell